Clinical trial NCT04079010: The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone
Official title: The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Flow Restriction
Growth Hormone
Strength Outcomes
Arginine
Keywords: blood flow restriction
growth hormone
strength outcomes
arginine
Lead sponsor: University of Mary Hardin-Baylor
Sponsor class: OTHER
First posted: 2019-09-06
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The current study will investigate the effects of Blood Flow Restriction (BFR) training and L-arginine supplementation on recreationally trained female participants. In particular, it will compare performance outcomes and blood markers among two intervention groups (BFR and BFR+Arg) and a control group (CON).

Detailed description: The current study will investigate the effects of Blood Flow Restriction (BFR) training and L-arginine supplementation on recreationally trained female participants. In particular, it will compare performance outcomes and blood markers among two intervention groups (BFR and BFR+Arg) and a control group (CON). All group will participate in the same training regimen. The control group will train and ingest a placebo pill. The BFR group will train with BFR and ingest a placebo pill, and the BFR+Arg group will train with BFR and ingest an L-arginine pill. All placebo pills will be Maltodextrin. The performance outcome is leg press 1RM, while the blood markers are growth hormone (GH) and cortisol. This analysis will provide insight as to whether or not L-arginine supplementation in addition to blood flow restriction training improves performance and muscle hypertrophy measure more than blood flow restriction training alone.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* PAR-Q form complete and without contraindications
* Body Mass Index (BMI) of 18.5-29.9 kg/m2
* Stable body weight prior to participation in the study (fluctuation not exceeding 10 lbs. within the past 6 months
* Agreement not to change current diet or exercise program (other than adding the program for the purpose of this study)

Exclusion Criteria:

* Any diagnosed orthopedic condition that prevents exercise
* BMI \> 29.9 kg/m2 or \< 18.5 kg/m2
* Affirmative answer to any of the questions presented on the PAR-Q form
* Are currently pregnant or planning to become pregnant during the study
* Currently taking blood pressure medication

Primary outcomes:
measure: Strength
timeFrame: Baseline measurements will be obtained during Week 0, then measurements will be taken at Week 4 and Week 8 to determine the amount of change in participant's strength at those particular time points compared to baseline
Secondary outcomes:
measure: Growth Factor
timeFrame: Measured at Week 0, Week 4, and Week 8 at the following intervals: prior to supplement, 15 and 30 minutes post-supplementation (before exercise), and 90 minutes post-supplementation (after exercise)
Other outcomes:
measure: Cortisol
timeFrame: Measured at Week 0, Week 4, and Week 8 at the following intervals: prior to supplement, 15 and 30 minutes post-supplementation (before exercise), and 90 minutes post-supplementation (after exercise)
Locations:
city: Belton
country: United States
facility: University of Mary Hardin-Baylor
state: Texas
Study officials:
References: